US Bancorp’s Elicio Therapeutics ELTX Stock Holding History

US Bancorp’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11	Closed	-$1K	–	4126
2021 Q3	$1K	Buy	+11	New	+$1.19K	﹤0.01%	3968

Other funds holding ELTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

US Bancorp's ELTX Position: Q4 2021 in Review

US Bancorp sold out of Elicio Therapeutics (ELTX) in Q4 2021, closing a stake of 11 shares — an estimated $1K sold.

US Bancorp first reported a position in ELTX in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 53 funds tracked by Wall St. Rank hold ELTX as of Q4 2021.

US Bancorp reported no remaining Elicio Therapeutics position as of Q4 2021 after selling out during the quarter.
US Bancorp sold 11 Elicio Therapeutics shares in Q4 2021, an estimated $1K.
US Bancorp first reported a position in Elicio Therapeutics in Q3 2021 and held it in 1 quarter.
US Bancorp's Elicio Therapeutics position peaked at $1K in Q3 2021.
53 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q4 2021.

Based on US Bancorp's 13F filing for Q4 2021, filed 11 Feb 2022.